CliffBio
small molecule

VALTURNA

ALISKIREN HEMIFUMARATE; VALSARTAN

Loss of exclusivityJuly 2026latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameVALTURNA
Active ingredientALISKIREN HEMIFUMARATE; VALSARTAN
StrengthEQ 300MG BASE;320MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
8168616July 2026product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VALTURNA patent cliff — loss of exclusivity July 2026 | CliffBio